Julianne Bruno, M.B.A., is a seasoned biotechnology executive with over two decades of experience in operations, strategy, and business development within the pharmaceutical and life sciences industries. Holding an M.B.A. from the Wharton School of the University of Pennsylvania, she began her career at Merck & Co., where she advanced through roles in global supply chain management and commercial operations. Bruno later held senior positions at Novartis and Genentech, honing her expertise in scaling manufacturing processes, regulatory compliance, and cross-functional team leadership during pivotal periods of company growth and product launches. As Chief Operating Officer at CRISPR Therapeutics AG from 2017 to 2021, Bruno played a instrumental role in transforming the pioneering gene-editing company from a research-focused startup into a clinical-stage leader. She oversaw all operational functions, including manufacturing, quality assurance, clinical supply chain, and facilities expansion, which were critical to advancing CRISPR's pipeline of investigational therapies for sickle cell disease, beta thalassemia, and cancer. Under her leadership, the company achieved key milestones, such as FDA authorization for its first CTX001 trial, strategic partnerships with Vertex Pharmaceuticals, and a successful IPO on NASDAQ, raising over $250 million to fuel R&D. Bruno's tenure at CRISPR solidified her reputation as a strategic operator capable of navigating complex regulatory landscapes and fostering innovation in cutting-edge therapies. Post-CRISPR, she has continued advising biotech ventures and serving on boards, leveraging her track record of driving operational excellence and value creation in high-stakes environments.